Good news for Jaleva’s‘Mast-R-Prep’ surgical skin prep market research.

Release issued 2nd June 2008

SAN DIEGO, CA, June 2, 2008 – Jaleva Pharmaceuticals LLC announces that market research results from FRANKLIN COMMUNICATIONS indicate that Mast-R-Prep, the company’s proprietary, chlorhexidine-based, one-step surgical skin prep, has the characteristics most desirable to general surgeons and orthopedic surgeons.

Jaleva’s Mast-R-Prep is the only one-step surgical skin prep product in the world that offers a combination of several desirable characteristics.  In contrast to other one-step surgical skin prep products, Mast-R-Prep has a long acting kill rate, is fast drying, easy to remove, has increased tackiness that promotes adhesion of drapes, and also utilizes a proprietary technology to trap and kill bacteria.

Participation included 100 respondents as follows: general surgeons (n=60) and orthopedic surgeons (n=40).  A subset of the independent findings included:

  • Confirmation that both DuraPrep and ChloraPrep are the leading surgical skin prep products. Each is currently used by approximately two-thirds of the survey participants. One Step Povidione Iodine ranks a distant third, with current usage cited by 41% of all respondents.
  • Ratings of Mast-R-Prep, based on the product profile provided, were exceptionally favorable. The 7-point scale used to measure surgeon interest resulted in a mean rating of 6.39, with approximately half of the respondents assigning the highest rating of “7”.
  • Mast-R-Prep’s long-acting kill rate was the top-rated contributor to its positive reception. Its fast-drying property and easy post-op removal ranked second and third, respectively. These address perceived shortcomings of the iodine-based DuraPrep.
  • The positive response to the convenience related attributes points to the potential shortcomings of ChloraPrep.

“We were able to measure 19 different characteristics of Surgical Skin Prep products, for all major products in this marketplace.  We were pleased to see that the independent findings showed Mast-R-Prep as a unique and superior product in both its antimicrobial properties as well as in its convenience related properties,” said Mordy Levine, Jaleva’s Chief Executive Officer.

According to Dr. Alex Battaglia, Jaleva President who coordinated the Time Kill and MIC Testing, “Mast-R-Prep is a one-step, chlorhexidine-based surgical skin prep that outperforms currently available surgical skin prep products.  It has several advantages and unique characteristics that surgeons will appreciate.

First, surgical drapes adhere to Mast-R-Prep formulation better than currently available surgical skin prep products.

Second, it has a unique bacteria trapping effect that prevents bacteria from migrating to the surgical wound.  Additionally, its tackiness makes Mast-R-Prep more easily detectable.  Mast-R-Prep dries faster and is more easily removed than currently available surgical skin prep products.

These unique properties and superior qualities will be desirable to surgeons and lead to a sizeable advantage over currently available surgical skin prep products.”

“We believe that Mast-R-Prep will supplant the use of currently available surgical skin prep products given their liabilities, and the desire expressed by surgeons for a product like Mast-R-Prep that meets all their needs.” says Mordy Levine.  “Not only does Mast-R-Prep have user-friendly qualities that surgeons will prefer over currently available surgical skin prep products, but we fully expect Mast-R-Prep to outperform and outlast currently available chlorhexidine-based surgical skin prep products in human efficacy testing scheduled over the next few weeks.”

Formed in 2000, Jaleva LLC is a privately held firm.  Jaleva is a leader in the application of its patented resin technology for the improvement of topical medications.  Jaleva is engaged in the research & development of delivery vehicles for active ingredients that treat onychomycosis, psoriasis, heel fissures (cracked heels), athlete’s foot and other dermatological conditions.

For inquiries regarding licensing of our products, please contact: Mordy Levine, CEO, 561–573–0094.

06-02-2008